Literature DB >> 1660340

Analysis of the p53 gene in human uterine carcinoma cell lines.

Y Yaginuma1, H Westphal.   

Abstract

The inactivation of the tumor suppressor gene p53 has been demonstrated in a variety of human tumors. In this study, we present a p53 gene analysis of 13 uterine carcinoma cell lines. Sequencing analysis of the entire coding region revealed mutations changing the p53 amino acid composition in all six endometrial carcinoma cell lines tested (Ishikawa, Hecl-A, Hecl-B, KLE, RL95-2, and AN-3). Of the seven cervical carcinoma cell lines, two (HT-3 and C-33A) contained p53 codon changes as well. We were unable to detect human papillomavirus in these two cell lines. By contrast, five human papillomavirus-positive cervical carcinoma cell lines (HeLa S-3, Caski, SiHa, C-4I, and ME-180) contained wild-type p53 gene sequences. We suggest that, in the human papillomavirus-positive cervical tumors, p53 inactivation occurred via the known mechanism of viral E6/cellular p53 protein association, whereas in all other tumors p53 function was compromised by changes in the amino acid sequence.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1660340

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells.

Authors:  S Tang; M Tao; J P McCoy; Z M Zheng
Journal:  Oncogene       Date:  2006-03-30       Impact factor: 9.867

2.  Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.

Authors:  Pang-ning Teng; Nicholas W Bateman; Kathleen M Darcy; Chad A Hamilton; George Larry Maxwell; Christopher J Bakkenist; Thomas P Conrads
Journal:  Gynecol Oncol       Date:  2015-01-02       Impact factor: 5.482

3.  Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro.

Authors:  H Saito; K Kitagawa; T Yoneda; Y Fukui; M Fujsawa; D Bautista; T Shirakawa
Journal:  Cancer Gene Ther       Date:  2017-06-16       Impact factor: 5.987

4.  Wild-type p53-induced phosphatase 1 dephosphorylates histone variant gamma-H2AX and suppresses DNA double strand break repair.

Authors:  Sung-Hwan Moon; Lin Lin; Xinna Zhang; Thuy-Ai Nguyen; Yolanda Darlington; Alan S Waldman; Xiongbin Lu; Lawrence A Donehower
Journal:  J Biol Chem       Date:  2010-01-29       Impact factor: 5.157

Review 5.  HEC-1 cells.

Authors:  Hiroyuki Kurarmoto; Mieko Hamano; Manami Imai
Journal:  Hum Cell       Date:  2002-06       Impact factor: 4.174

6.  Immunohistochemical detection of p53 in cervical epithelial lesions with or without infection of human papillomavirus types 16 and 18.

Authors:  M Akasofu; Y Oda
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

7.  Establishment and characterization of a new human cell line (EJ) derived from endometrial carcinoma.

Authors:  Keiichi Isaka; Hirotaka Nishi; Toshihide Nakada; Yumi Osakabe; Mitsuyasu Hokamura; Hiromi Serizawa; Yoshiro Ebihara; Masaomi Takayama
Journal:  Hum Cell       Date:  2002-12       Impact factor: 4.174

8.  Dichloroacetate induces apoptosis in endometrial cancer cells.

Authors:  Jason Y Y Wong; Gordon S Huggins; Marcella Debidda; Nikhil C Munshi; Immaculata De Vivo
Journal:  Gynecol Oncol       Date:  2008-04-18       Impact factor: 5.482

9.  Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53.

Authors:  F Hoppe-Seyler; K Butz
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.

Authors:  Peixin Dong; Zhujie Xu; Nan Jia; Dajin Li; Youji Feng
Journal:  Mol Cancer       Date:  2009-11-16       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.